Weekly Investment Analysts’ Ratings Changes for Revance Therapeutics (RVNC)

Revance Therapeutics (NASDAQ: RVNC) recently received a number of ratings updates from brokerages and research firms:

  • 1/5/2018 – Revance Therapeutics had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $54.00 price target on the stock.
  • 1/4/2018 – Revance Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $44.00 price target on the stock.
  • 1/4/2018 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/19/2017 – Revance Therapeutics was given a new $40.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 12/13/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/8/2017 – Revance Therapeutics had its price target raised by analysts at SunTrust Banks, Inc. to $53.00. They now have a “buy” rating on the stock.
  • 12/6/2017 – Revance Therapeutics had its price target raised by analysts at Mizuho from $37.00 to $54.00. They now have a “buy” rating on the stock.
  • 12/5/2017 – Revance Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $42.00 price target on the stock.
  • 12/5/2017 – Revance Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $28.00 to $51.00. They now have an “overweight” rating on the stock.
  • 12/5/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/4/2017 – Revance Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/29/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/27/2017 – Revance Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $31.00 price target on the stock.
  • 11/16/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/16/2017 – Revance Therapeutics is now covered by analysts at Mizuho. They set a “buy” rating and a $37.00 price target on the stock.

Revance Therapeutics Inc (RVNC) traded down $1.00 during mid-day trading on Friday, hitting $34.90. 697,856 shares of the company traded hands, compared to its average volume of 874,885. The company has a market capitalization of $1,080.00, a PE ratio of -9.16 and a beta of 1.62. Revance Therapeutics Inc has a one year low of $18.00 and a one year high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the company posted ($0.64) earnings per share. sell-side analysts predict that Revance Therapeutics Inc will post -3.73 EPS for the current year.

In related news, Director Mark J. Foley acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at $161,760. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the transaction, the chief executive officer now owns 133,188 shares in the company, valued at $3,321,708.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,426 shares of company stock worth $956,026. 18.86% of the stock is owned by company insiders.

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply